Clinical trial
Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract…
NCT00259831 · CV Technologies, Industry · Completed
Key facts
| NCT number | NCT00259831 |
|---|---|
| Title | Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults |
| Official title | Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adult Employees in Continuing Care Facilities |
| Lead sponsor | CV Technologies, Industry |
| Collaborators | Capital Health, Canada |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Upper Respiratory Infection |
| Intervention type | Drug |
| Interventions | CVT-E002 (Cold-FX), a natural health product |
| Enrollment | 500 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Dec 1, 2005 |
| Last update posted | Jun 8, 2009 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: